Robert E. Waltermire
CIK 1876996 · Senior VP, Chief Pharma Dev. · last filed 2025-03-07
Robert E. Waltermire is a Senior VP, Chief Pharma Dev. who has filed 15 SEC Form 4 insider transactions across 1 company since 2021. The most recent filing, for MDGL, was dated Mar 7, 2025. Across all open-market trades the lifetime net is −$11.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $6.7M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$6.74M
1
15
-$11.25M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MDGL | Senior VP, Chief Pharma Dev. | 14,018 | $480.77 | $6.74M | -$11.25M | 15 | 2025-03-07 |
Recent Filings
15 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-03-07 | MDGL | Mixed | +2,061 | -$3.58M | EDGAR |
| 2025-03-04 | MDGL | Sell (S) | −1,227 | -$418.5K | EDGAR |
| 2025-01-27 | MDGL | Sell (S) | −103 | -$34.5K | EDGAR |
| 2025-01-17 | MDGL | Sell (S) | −442 | -$120.8K | EDGAR |
| 2024-06-18 | MDGL | Mixed | — | -$366.5K | EDGAR |
| 2024-06-14 | MDGL | Mixed | — | -$394.2K | EDGAR |
| 2024-05-23 | MDGL | Sell (S) | −1,036 | -$239.7K | EDGAR |
| 2024-01-25 | MDGL | Grant (A) | +1,419 | $0 | EDGAR |
| 2024-01-18 | MDGL | Tax (F) | −550 | -$134.2K | EDGAR |
| 2023-12-18 | MDGL | Mixed | — | -$590.3K | EDGAR |